CN101115744B - 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐 - Google Patents

制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐 Download PDF

Info

Publication number
CN101115744B
CN101115744B CN2005800476248A CN200580047624A CN101115744B CN 101115744 B CN101115744 B CN 101115744B CN 2005800476248 A CN2005800476248 A CN 2005800476248A CN 200580047624 A CN200580047624 A CN 200580047624A CN 101115744 B CN101115744 B CN 101115744B
Authority
CN
China
Prior art keywords
azd0530
compound
solvent
mixture
eligibly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800476248A
Other languages
English (en)
Chinese (zh)
Other versions
CN101115744A (zh
Inventor
J·G·福特
J·F·麦克卡比
A·奥克阿尼-麦克穆兰
P·奥基弗
S·M·波因通
L·鲍威尔
M·普尔迪
J·威思纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101115744A publication Critical patent/CN101115744A/zh
Application granted granted Critical
Publication of CN101115744B publication Critical patent/CN101115744B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2005800476248A 2004-12-17 2005-12-14 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐 Expired - Lifetime CN101115744B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0427697.8 2004-12-17
GBGB0427697.8A GB0427697D0 (en) 2004-12-17 2004-12-17 Chemical process
PCT/GB2005/004807 WO2006064217A2 (en) 2004-12-17 2005-12-14 PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF

Publications (2)

Publication Number Publication Date
CN101115744A CN101115744A (zh) 2008-01-30
CN101115744B true CN101115744B (zh) 2012-02-01

Family

ID=34090249

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800476248A Expired - Lifetime CN101115744B (zh) 2004-12-17 2005-12-14 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐

Country Status (16)

Country Link
US (1) US8304417B2 (https=)
EP (1) EP1871769B1 (https=)
JP (2) JP5161584B2 (https=)
KR (6) KR20080094847A (https=)
CN (1) CN101115744B (https=)
AU (2) AU2005315458B2 (https=)
BR (1) BRPI0519085A2 (https=)
CA (2) CA2590735C (https=)
ES (1) ES2622480T3 (https=)
GB (1) GB0427697D0 (https=)
IL (1) IL183525A0 (https=)
MX (1) MX2007007210A (https=)
NO (1) NO20072755L (https=)
NZ (1) NZ555468A (https=)
WO (1) WO2006064217A2 (https=)
ZA (1) ZA200704532B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CN103275072B (zh) * 2013-05-22 2016-01-20 苏州明锐医药科技有限公司 塞卡替尼的制备方法
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US10369152B2 (en) 2015-02-13 2019-08-06 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
PT3930715T (pt) 2019-02-27 2024-08-02 Astrazeneca Ab Saracatinib para uso no tratamento de fibrose pulmonar idiopática
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434821A (zh) * 2000-06-06 2003-08-06 阿斯特拉曾尼卡有限公司 治疗肿瘤用的喹唑啉衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2419301C (en) 2000-08-21 2009-12-08 Astrazeneca Ab Quinazoline derivatives
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0307333D0 (en) 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1434821A (zh) * 2000-06-06 2003-08-06 阿斯特拉曾尼卡有限公司 治疗肿瘤用的喹唑啉衍生物

Also Published As

Publication number Publication date
ZA200704532B (en) 2008-07-30
CN101115744A (zh) 2008-01-30
KR20080094847A (ko) 2008-10-24
US8304417B2 (en) 2012-11-06
EP1871769A2 (en) 2008-01-02
KR20080094846A (ko) 2008-10-24
KR20110114727A (ko) 2011-10-19
US20090099196A1 (en) 2009-04-16
CA2675642A1 (en) 2006-06-22
EP1871769B1 (en) 2017-02-22
JP5161584B2 (ja) 2013-03-13
KR20080094849A (ko) 2008-10-24
AU2005315458B2 (en) 2009-03-12
AU2005315458A1 (en) 2006-06-22
CA2590735C (en) 2009-11-10
BRPI0519085A2 (pt) 2008-12-23
NZ555468A (en) 2010-12-24
WO2006064217A3 (en) 2006-12-21
WO2006064217A2 (en) 2006-06-22
WO2006064217A8 (en) 2007-07-05
MX2007007210A (es) 2007-11-07
IL183525A0 (en) 2007-09-20
AU2009200622A1 (en) 2009-03-12
KR20070090004A (ko) 2007-09-04
JP2008524183A (ja) 2008-07-10
CA2590735A1 (en) 2006-06-22
JP2009143920A (ja) 2009-07-02
NO20072755L (no) 2007-07-02
ES2622480T3 (es) 2017-07-06
KR20080094848A (ko) 2008-10-24
GB0427697D0 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
AU727013B2 (en) Heterocyclic compound and antitumor agent comprising the same as effective component
JPH11504033A (ja) キナゾリン誘導体
JPH11504031A (ja) キナゾリン誘導体
CN116322678A (zh) Jak抑制剂的盐型、晶型及其制备方法和应用
JPH11507329A (ja) キナゾリン誘導体
JPH11504034A (ja) キナゾリン誘導体
JPH11504032A (ja) キナゾリン誘導体
TW200840581A (en) Novel pyrimidine derivatives
JP2002513009A (ja) Ｎ−（３−エチニルフェニルアミノ）−６，７−ビス（２−メトキシエトキシ）−４−キナゾリンアミンメシレートの無水物及び一水和物
EP2269994B1 (en) The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof
CN101115744B (zh) 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐
CN102812010B (zh) 喹唑啉衍生物及其制备方法和应用
TWI443095B (zh) 新穎鹽
EP3471730B1 (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
WO2002002534A1 (en) Quinazolines with therapeutic use
CN101932326A (zh) 4-苯胺喹唑啉衍生物的制药用途
CN111566101B (zh) Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
JP2007534733A (ja) 血管損傷剤として使用する３，４−ジ置換マレイミド
WO2017211216A1 (zh) 稠合嘧啶哌啶环衍生物及其制备方法和应用
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
WO2008046242A1 (fr) Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
EP4653445A1 (en) Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof
CN121873051A (zh) 多环类间变性淋巴瘤激酶抑制剂的盐及晶型
WO2023010354A1 (zh) 一种具有egfr抑制活性的小分子化合物及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20120201